At a glance Selected evidence in this atlas Studied use & population Adults with obesity, or overweight plus a weight-related condition, without diabetes
Study context Selected efficacy evidence 11.2% reported weight loss · 2.1% loss with placebo · 72 weeks
ATTAIN-1 · Phase 3 · peer-reviewed · 36 mg once-daily trial capsule (bioequivalent approved tablet: 17.2 mg) · Regardless of stopping treatment
Evidence & limitations Important safety context GI effects predominated; adverse-event discontinuation at top dose 10.3%.
Safety context Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
At a glance Evidence & safety Development timeline Biology & identity Molecule
Evidence in the atlas 2 results Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
Weight loss 11.2% reported weight loss · 2.1% loss with placebo · 72 weeks
36 mg once-daily trial capsule (bioequivalent approved tablet: 17.2 mg)
Adults with obesity, or overweight plus a weight-related condition, without diabetes
Published treatment-regimen estimand in the intention-to-treat population FDA-approved April 1, 2026 for adult weight management (Foundayo)
Safety context GI effects predominated; adverse-event discontinuation at top dose 10.3%.
Limitations: Published trial estimate is 11.2%; subsequent label/approval communication reports 11.1%. Capsule and tablet milligram strengths differ.
Glucose control 1.91 percentage-point HbA1c decrease · 1.47 pp decrease with Oral semaglutide 14 mg · 52 weeks
36 mg daily trial capsule
Adults with type 2 diabetes
Treatment-regimen estimate, regardless of treatment discontinuation or additional glucose-lowering therapy.
Safety context GI events 58%; adverse-event discontinuation about 10%.
Limitations: Open-label; trial-wide baseline. Trial capsule strength must not be equated milligram-for-milligram with marketed tablets.
Biology & identity Status in this atlas: FDA-approved April 1, 2026 for adult weight management (Foundayo) Status source
Hormone activity An oral small molecule that activates the human GLP-1 receptor.
What do these hormones do? GLP-1
Foundayo U.S. oral weight-management brand for adults with obesity or overweight with a weight-related condition. The July 2026 label is for weight management, not a standalone type 2 diabetes indication. · oral Eli Lilly and Company · Exclusive global development and commercialization licensee; manufacturer of Foundayo.; Chugai Pharmaceutical · Originator; discovered orforglipron and licensed it to Lilly.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule 2D chemical structure Orforglipron · 2D chemical structure Chemical connectivity and stereochemistry of Orforglipron.
Shown: Active compound as represented in the named PubChem record; formulation excipients excluded.
A two-dimensional chemical diagram shows bonds and stereochemistry, not a measured three-dimensional shape.
PubChem, National Library of Medicine
PubChem CID 137319706 Development timeline Next milestone A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history 5 selected milestones Orforglipron · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
Sep 2018
Chugai licenses the program to Lilly Chugai granted Lilly worldwide development and commercialization rights. The source establishes the month, not an exact signing day.
Source Jun 21, 2025
ACHIEVE-1 diabetes results published Phase 3 results in early type 2 diabetes were published; diabetes efficacy research is distinct from an approved diabetes indication.
Source Sep 16, 2025
ATTAIN-1 obesity results published The 72-week phase 3 obesity trial without diabetes was published, supporting the weight-management development program.
Source Apr 1, 2026
Foundayo approved in the U.S. FDA approved orforglipron for adult weight management; Chugai's April 2 announcement identifies April 1 as Lilly's U.S. approval announcement date.
Source Sep 29, 2026 Announcement
Orforglipron comparison extends to oral semaglutide 25 mg A covariate-adjusted indirect analysis compares orforglipron 17.2 mg against oral semaglutide 25 mg in adults with type 2 diabetes. This is not the ACHIEVE-3 randomized comparison against oral semaglutide 14 mg. Cross-study assumptions and treatment-adherent estimands limit causal interpretation.
Source Selected sources checked Sep 29, 2026. This is not an exhaustive history.
